Eli Lilly allows Cipla to sell weight loss drug under new brand in India

Core Insights - Eli Lilly has entered into an agreement with Cipla, permitting the Indian pharmaceutical company to market its popular weight-loss medication under a different brand in India [1] Company Summary - Eli Lilly has signed a deal with Cipla, which allows the latter to sell Eli Lilly's weight-loss drug in India [1] - The agreement highlights Eli Lilly's strategy to expand its market presence through partnerships with local companies [1] Industry Summary - The collaboration between Eli Lilly and Cipla reflects the growing trend of international pharmaceutical companies partnering with local firms to enhance distribution and accessibility of medications in emerging markets like India [1]